56433-01-3

Basic information

• Product Name: 2-(bromomethyl)-1-chloro-3-nitrobenzene
• Synonyms: 2-(bromomethyl)-1-chloro-3-nitrobenzene;6-Chloro-2-nitrobenzyl bromide;Einecs 260-179-8
• CAS NO: 56433-01-3
• Molecular Formula: C₇H₅BrClNO₂
• Molecular Weight: 250.4771
• EINECS: 260-179-8
• Mol File: 56433-01-3.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 295.6°C at 760 mmHg
• Flash Point: 132.6°C
• Appearance: /
• Density: 1.755
• Vapor Pressure: 0.00266mmHg at 25°C
• Refractive Index: 1.6110 (estimate)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-(bromomethyl)-1-chloro-3-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(bromomethyl)-1-chloro-3-nitrobenzene(56433-01-3)
• EPA Substance Registry System: 2-(bromomethyl)-1-chloro-3-nitrobenzene(56433-01-3)

Safety Data

• Hazardous Substances Data: 56433-01-3(Hazardous Substances Data)

Usage

Description

2-(Bromomethyl)-1-chloro-3-nitrobenzene is an organic compound characterized by its bromine and chlorine substituents on the benzene ring, along with a nitro group. It is a versatile intermediate in the synthesis of various pharmaceuticals and chemical compounds due to its reactive functional groups.

Uses

Used in Pharmaceutical Synthesis:
2-(Bromomethyl)-1-chloro-3-nitrobenzene is used as a key reactant in the synthesis of cyclic hydroxamic acid PF-04859989. 2-(bromomethyl)-1-chloro-3-nitrobenzene serves as a potent and selective inhibitor of human and rat Kynurenine aminotransferase II (KAT II), which is an enzyme involved in the metabolism of tryptophan. Inhibition of KAT II is a potential therapeutic strategy for the treatment of schizophrenia, as it may help regulate the levels of certain neurotransmitters in the brain.
Used in Chemical Research:
In addition to its pharmaceutical applications, 2-(bromomethyl)-1-chloro-3-nitrobenzene can be utilized in chemical research as a starting material for the development of new compounds with various potential applications. Its unique structure allows for further functionalization and modification, making it a valuable tool in the synthesis of novel molecules for a range of industries, including materials science, agrochemicals, and more.

InChI:InChI=1/C7H5BrClNO2/c8-4-5-6(9)2-1-3-7(5)10(11)12/h1-3H,4H2

Upstream product

• 83-42-1 6-chloro-2-nitrotoluene 
• 50907-57-8 (2-chloro-6-nitrobenzene)methanol 
• 88-72-2 1-methyl-2-nitrobenzene 
• 7726-95-6 bromine 

Downstream Products

• 6361-22-4 2-chloro-6-nitrobenzaldehyde 
• 50907-57-8 (2-chloro-6-nitrobenzene)methanol 
• 66354-66-3 4-chloro-2-phenyl-1H-indole 
• 31912-08-0 (2-chloro-6-nitro-phenyl)-acetic acid 
• 220327-45-7 2-(2-chloro-6-nitrophenyl)acetophenone 
• 220327-49-1 9-Chloro-2-phenyl-4,5-dihydro-pyrrolo[3,2,1-ij]quinolin-6-one 
• 220327-46-8 4-chloro-1-(2-cyanoethyl)-2-phenylindole 
• 220327-47-9 3-(4-chloro-2-phenylindol-1-yl)propionic acid 
• 333954-56-6 diethyl 2-[(2-chloro-6-nitro-phenyl)methyl]propanedioate 
• 882023-24-7 2-oxo-1,2,3,4-tetrahydroquinoline-5-carbonitrile 
• 72995-15-4 5-chloro-3,4-dihydro-2(1H)-quinolinone 
• 1247021-83-5 diethyl (2-amino-6-chlorobenzyl)propanedioate 
• 95196-89-7 1-(2-chloro-6-nitro-benzyl)-pyridinium; bromide 

Relevant articles and documents

NOVEL FUNGICIDAL CARBAMATE COMPOUNDS

An object of the present invention is to provide a carbamate compound or a salt thereof that controls diseases. The present invention provides a carbamate compound represented by Formula (1), or a salt thereof, wherein R1, R3 and R6 are identical or different and each represents hydrogen, or the like; R2 represents hydrogen, halogen, or C1-6 alkyl; R4 and R5 are identical or different and each represents hydrogen, or the like; R7 represents hydrogen, or the like; R8 represents hydrogen, or C1-6 alkyl; X and Χ1 independently represent oxygen, or sulfur; Y represents oxygen, or sulfur; Z represents oxygen/ or sulfur; l is an integer of 0 to 2; m is an integer of 0 to 3; n is an integer of 0 to 4; and when l, m or n is more than one, the l, m or n may be the same or different.

NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R15, R16, R17 and n are as described herein, compositions including the compounds and methods of using the compounds.

EP2/4 AGONISTS

EP2/4 compounds having improved dual pharmacological activity are described. The uniqueness of using EP2/4 dual agonists resides in their ability to modify both uveoscleral outflow via the ciliary muscle and conventional outflow via trabecular meshwork and Schlemm's canal all in the same treatment paradigm. The compounds can be employed for the treatment of glaucoma and ocular hypertension. Formula (I).